The product is administered rectally. Each suppository contains as a key ingredient human recombinant interferon alpha-2b in the specified levels(150,000 IU, 500,000 IU, 1,000,000 IU, 3,000,000 IU).
Acute respiratory viral irritation, including influenza, including those complicated by bacterial irritation, pneumonia (bacterial, viral, chlamydial) in children and adults as part of comprehensive support.
The recommended level for adults, including pregnant women and children over 7 years of age, is VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 5 days. Support may be continued based on indications.
For children up to 7 years old, including newborns and premature babies with a gestational age of more than 34 weeks, it is recommended to use VIFERON® 150,000 IU per 1 suppository twice a day every 12 hours daily for 5 days. Support may be continued based on indications. The interval between courses is 5 days.
For premature newborns with a gestational age of less than 34 weeks, it is recommended to use VIFERON® 150,000 IU per 1 suppository three times a day every 8 hours daily for 5 days. Support may be continued based on indications. The interval between courses is 5 days.
Irritation conditions of newborns, including premature babies: meningitis (bacterial, viral), sepsis, intrauterine irritation (chlamydia, herpes, cytomegalovirus irritation, enterovirus irritation, candidiasis, including visceral, mycoplasmosis) as part of comprehensive support.
The recommended level for newborns, including premature babies with a gestational age of more than 34 weeks, is VIFERON® 150,000 IU once daily per 1 suppository twice a day every 12 hours. The course is 5 days.
For premature newborns with a gestational age of less than 34 weeks, it is recommended to use VIFERON® 150,000 IU once daily per 1 suppository three times a day every 8 hours. The course is 5 days.
The recommended number of courses for various irritation conditions: sepsis – 2-3 courses, meningitis – 1-2 courses, herpes irritation – 2 courses, enterovirus irritation – 1-2 courses, cytomegalovirus infection – 2-3 courses, mycoplasmosis, candidiasis, including visceral – 2-3 courses. The interval between courses is 5 days. Support may be continued based on indications.
Chronic viral hepatitis B, C, D in children and adults as part of comprehensive support, including in combination with plasmapheresis and hemosorption for chronic viral hepatitis with severe activity, complicated by liver cirrhosis.
The recommended level for adults is VIFERON® 3,000,000 IU per 1 suppository twice a day every 12 hours daily for 10 days, then three times a week every other day for 6-12 months. The duration is determined by effectiveness and laboratory parameters.
For children under 6 months of age, a level of 300,000-500,000 IU per day is recommended; for children aged 6 to 12 months – 500,000 IU per day.
For children aged 1 year to 7 years, a level of 3,000,000 IU per 1 m2 of body surface area per day is recommended.
For children over 7 years of age, a level of 5,000,000 IU per 1 m2 of body surface area per day is recommended.
The product is administered twice a day every 12 hours for the first 10 days daily, then three times a week every other day for 6-12 months. The duration is determined by effectiveness and laboratory parameters.
The daily level of the product for each patient is calculated by multiplying the recommended use for the age by the body surface area calculated using the Garford, Terry, and Rurk nomogram for calculating body surface area based on height and weight. The single use is calculated by dividing the calculated daily use by 2 administrations, and the resulting value is rounded up to the suppository usage.
For chronic viral hepatitis with severe activity and liver cirrhosis before plasmapheresis and/or hemosorption, it is recommended to use VIFERON® 150,000 IU for children under 7 years of age, and VIFERON® 500,000 IU for children over 7 years of age, 1 suppository twice a day every 12 hours daily for 14 days.
Irritation condition of the urogenital tract (chlamydia, cytomegalovirus irritation, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus irritation, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults, including pregnant women, as part of comprehensive support.
The recommended use for adults is VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 5-10 days. Support may be continued based on indications.
For pregnant women from the second trimester of pregnancy (starting from the 14th week of gestation), it is recommended to use VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 10 days, then for 9 days, 3 times with an interval of 3 days (on the fourth day) per 1 suppository twice a day every 12 hours. Then every 4 weeks until delivery, VIFERON® 150,000 IU per 1 suppository twice a day every 12 hours daily for 5 days. If necessary, it is recommended to use the product before delivery (from the 38th week of gestation) VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 10 days.
Primary or recurrent herpetic irritation of the skin and mucous membranes, localized form, mild to moderate course, including urogenital form in adults, including pregnant women.
The recommended use for adults is VIFERON® 1,000,000 IU per 1 suppository twice a day every 12 hours daily for 10 days and more for recurrent irritation. Support may be continued based on indications. It is recommended to start support immediately at the first signs of skin and mucous membrane lesions (itching, burning, redness). For the support of recurrent herpes, it is desirable to start support in the prodromal period or at the onset of signs of recurrence.
For pregnant women from the second trimester of pregnancy (starting from the 14th week of gestation), it is recommended to use VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 10 days, then for 9 days, 3 times with an interval of 3 days (on the fourth day) per 1 suppository twice a day every 12 hours. Then every 4 weeks until delivery, VIFERON® 150,000 IU per 1 suppository twice a day every 12 hours daily for 5 days. If necessary, it is recommended to use the product before delivery (from the 38th week of gestation) VIFERON® 500,000 IU per 1 suppository twice a day every 12 hours daily for 10 days.
Viral meningitis in children aged 4 years and older as part of comprehensive support.
The recommended use for children from 4 to 11 years old is VIFERON® 1,000,000 IU per 1 suppository twice a day every 12 hours daily for 7 days, then 1,000,000 IU per 1 suppository once a day (at night) daily
